Read on Twitter
I have substantially bought #DDDD today
I have done extensive research into #COVID19 treatments companies listed on AIM over the weekend (Around 30 HOURS
) and came to the conclusions DDDD is the drug which is most likely to have great efficacy and safety data 
I have done extensive research into #COVID19 treatments companies listed on AIM over the weekend (Around 30 HOURS
) and came to the conclusions DDDD is the drug which is most likely to have great efficacy and safety data
#DDDD
The Microbiome Therapeutics company focused on using an innovative solutions for treatment in unmet 21st century ailments
Areas of focus
-Vaccines
-Oncology (Cancer)
-Respiratory illnesses inc
---SARS-CoV-2 #COVID19
-Irritable Bowel Syndrome
-Central Nervous System
The Microbiome Therapeutics company focused on using an innovative solutions for treatment in unmet 21st century ailments
Areas of focus
-Vaccines
-Oncology (Cancer)
-Respiratory illnesses inc
---SARS-CoV-2 #COVID19
-Irritable Bowel Syndrome
-Central Nervous System
#DDDD 
Firstly, I would like to draw your attention towards the extensive co operation between 4D and @Merck
Merck are a $200b company
With the 4th Largest drug in the world
KEYTRUDER
(based on $7+ billion Revenues in 2019) https://www.pharmaceutical-technology.com/features/top-selling-prescription-drugs/
Firstly, I would like to draw your attention towards the extensive co operation between 4D and @Merck
Merck are a $200b company
With the 4th Largest drug in the world
KEYTRUDER
(based on $7+ billion Revenues in 2019) https://www.pharmaceutical-technology.com/features/top-selling-prescription-drugs/
#DDDD
@Merck currently have signed 2 collaborations with #DDDD
1- To develop their KEYTRUDER BLOCKBUSTER Drug in conjunction with #DDDD MicroRx Platform
(Initiated 2018)
2- To develop multiple novel Vaccines via Live Bio-therapeutics
(Initiated 2019)
@Merck currently have signed 2 collaborations with #DDDD
1- To develop their KEYTRUDER
BLOCKBUSTER Drug in conjunction with #DDDD MicroRx Platform (Initiated 2018)
2- To develop multiple novel Vaccines via Live Bio-therapeutics
(Initiated 2019)
#DDDD
@Merk along with other very reputable high grade investment firms make up 70.9% of share holding.
This is a massive sign of confidence/validation of the project therapeutic area which they are innovators in
@Merk along with other very reputable high grade investment firms make up 70.9% of share holding.
This is a massive sign of confidence/validation of the project therapeutic area which they are innovators in
#DDDD
I myself have done vigorous research on the link between a healthy gut/microbiome and overall health.
Clinical researchers coming from the most prestigious Universities such as Harvard back up the thesis that ailments can be cured by cultivating the correct gut bacteria
I myself have done vigorous research on the link between a healthy gut/microbiome and overall health.
Clinical researchers coming from the most prestigious Universities such as Harvard back up the thesis that ailments can be cured by cultivating the correct gut bacteria
#DDDD
Here is a short video created by Cancer Research UK validating Gut Bacteria can play a vital role in reducing inflammation and CURING CANCER
Here is a short video created by Cancer Research UK validating Gut Bacteria can play a vital role in reducing inflammation and CURING CANCER
#DDDD
A VERY INTERESTING WATCH- FOR YOUR POCKET AND HEALTH
Here is another Bio Chemist that hypothesises
The Microbiome is the central hub for health, energy and well being, validating the future to treating illnesses can be via the microbiome
A VERY INTERESTING WATCH- FOR YOUR POCKET AND HEALTH Here is another Bio Chemist that hypothesises
The Microbiome is the central hub for health, energy and well being, validating the future to treating illnesses can be via the microbiome
#DDDD
#DDDD + @Merck's collaboration are working with terminally ill patients who have advanced stage cancers
Generally, the most aggressive resistant cancers which unfortunately have limited treatment options and a significant mortality rate
#DDDD + @Merck's collaboration are working with terminally ill patients who have advanced stage cancers
Generally, the most aggressive resistant cancers which unfortunately have limited treatment options and a significant mortality rate
#DDDD
Cancer Trial with @Merck
#DDDD PURE INNOVATION
Leading the way in the Cancer Microbiome field, improving one of the best selling drugs in the world
Ray Dalio
'It is so important to focus on hard assets and innovators in these markets, they are the real winners'
Cancer Trial with @Merck
#DDDD PURE INNOVATION
Leading the way in the Cancer Microbiome field, improving one of the best selling drugs in the world
Ray Dalio
'It is so important to focus on hard assets and innovators in these markets, they are the real winners'
#DDDD
Results thus far
3/6 of the First Patients indicate positive results.
This is SPECTACULAR for Stage 4 Cancer patients.
When all hope is lost...
NSCLC-AFTER 7 FAILED CANCER TREATMENTS this treatment finally starts to offer light at the end of the tunnel
Results thus far
3/6 of the First Patients indicate positive results.
This is SPECTACULAR for Stage 4 Cancer patients.
When all hope is lost...
NSCLC-
AFTER 7 FAILED CANCER TREATMENTS this treatment finally starts to offer light at the end of the tunnel
#DDDD
Now look at RCC top
This patient has shown consistent regression
One tumour COMPLETE DISAPPEARANCE
We are talking stage 4 Cancer with huge tumour regression
This is rare!
Can you see why @Merck have bought 7% of #DDDD and signed a $347m deal to create vaccines
Now look at RCC top
This patient has shown consistent regression
One tumour COMPLETE DISAPPEARANCE
We are talking stage 4 Cancer with huge tumour regression
This is rare!
Can you see why @Merck have bought 7% of #DDDD and signed a $347m deal to create vaccines
#DDDD
Thank you to @AIM_bagger for pointing out this is $347m per vaccine created
This equates to in excess of $1 BILLION in milestone payments plus Royalty payments on sales
Thank you to @AIM_bagger for pointing out this is $347m per vaccine created
This equates to in excess of $1 BILLION in milestone payments plus Royalty payments on sales
#DDDD
I'm telling you this is INNOVATION!
I haven't even got onto their #COVID19 Potential treatment yet!
I'm telling you this is INNOVATION!
I haven't even got onto their #COVID19 Potential treatment yet!
#DDDD
Why may #DDDD have an instrumental treatment technique that may assist in the FIGHT AGAINST #COVID19?
Why may #DDDD have an instrumental treatment technique that may assist in the FIGHT AGAINST #COVID19?
#DDDD
#COVID19 Background
I have done extensive research into what is causing these severe #SARS_COV_2 cases
These cases are heavily linked to the immune system going into over drive creating #CytokineStorm
#COVID19 Background
I have done extensive research into what is causing these severe #SARS_COV_2 cases
These cases are heavily linked to the immune system going into over drive creating #CytokineStorm
#DDDD
Cytokine storm= AN UNCONTROLLED RELEASE OF CYTOKINES By Macrophage
Cytokines such as Interferons and Interleukin play a role in the immune system over reacting, creating too much inflammation which then causes a range of other issues which spiral out of control
Cytokine storm= AN UNCONTROLLED RELEASE OF CYTOKINES By Macrophage
Cytokines such as Interferons and Interleukin play a role in the immune system over reacting, creating too much inflammation which then causes a range of other issues which spiral out of control
#DDDD
Where does #DDDD treatment come into play?
Cytokines wake up Neutrophils which excrete Neutrophil Extracellular Traps
As seen in the video NETS create inflammation which makes it increasingly difficult for Gas Exchange in the Lungs
Where does #DDDD treatment come into play?
Cytokines wake up Neutrophils which excrete Neutrophil Extracellular Traps
As seen in the video NETS create inflammation which makes it increasingly difficult for Gas Exchange in the Lungs
#DDDD
Neutrophils also create
-Proteinaise
-ROS-Creates cell death and does not discriminate taking out both healthy and virus cells
Neutrophils also create
-Proteinaise
-ROS-
Creates cell death and does not discriminate taking out both healthy and virus cells
#DDDD
Notice how the video talks about positive data in mice models?
Is this video highlighting data from #DDDD?
Notice how the video talks about positive data in mice models?
Is this video highlighting data from #DDDD?
#DDDD
To conclude
These 2 trials in both Cancer and #COVID19 represent near term exponentiation inflection points for this young innovative pharma
- #COVID19 Trials are expected to begin imminently
-Update/Readout from Cancer Trial progression is expected Q2 (This Q)
To conclude
These 2 trials in both Cancer and #COVID19 represent near term exponentiation inflection points for this young innovative pharma
- #COVID19 Trials are expected to begin imminently
-Update/Readout from Cancer Trial progression is expected Q2 (This Q)
#DDDD
Director in the attached presentation highlights completion of enrolment for Part A of the P1/2 Cancer Trial in collaboration with @Merck on 16th March
https://www.4dpharmaplc.com/application/files/2015/8401/4673/4D_Pharma_plc_Chardan_MM_Summit_Presentation_16.03.20.mp4
Director in the attached presentation highlights completion of enrolment for Part A of the P1/2 Cancer Trial in collaboration with @Merck on 16th March
https://www.4dpharmaplc.com/application/files/2015/8401/4673/4D_Pharma_plc_Chardan_MM_Summit_Presentation_16.03.20.mp4
#DDDD
Key take homes from today's RNS regarding Cancer Trial in conjunction with @Merck KEYTRUDER drug, highlighted below
Phase 1 Success
Remember this is open label, so expect results as we progress
One to tuck away and in a couple of years likely to have 10 Bagged
Key take homes from today's RNS regarding Cancer Trial in conjunction with @Merck KEYTRUDER
drug, highlighted belowPhase 1 Success
Remember this is open label, so expect results as we progress
One to tuck away and in a couple of years likely to have 10 Bagged
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Phase 1 Demonstrated
-Excellent Safety Profile
-No Drug discontinuation due to drug side effects
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Phase 1 Demonstrated
-Excellent Safety Profile
-No Drug discontinuation due to drug side effects
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Out of the 12 Patients
-5 withdrawn from the study due to Cancer Progression Serious Adverse Events
This is due to the nature of the patient which #DDDD are trying to treat. (Stage 4 Terminally Ill)
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Out of the 12 Patients
-5 withdrawn from the study due to Cancer Progression Serious Adverse Events
This is due to the nature of the patient which #DDDD are trying to treat. (Stage 4 Terminally Ill)
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Analyse the data in 2 cohorts
Discounting the people that dropped out due to their own personal reasons, too soon into treatment
Mid case (Discount 3
)
5/9= PR 55%
High Case (Discount 5
)
5/7= PR 71%
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Analyse the data in 2 cohorts
Discounting the people that dropped out due to their own personal reasons, too soon into treatment
Mid case (Discount 3
) 5/9= PR 55%
High Case (Discount 5
)5/7= PR 71%
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
By interpreting the data you can see a
55-71% of Stage 4 Terminally ill Cancer patients are showing PR (Positive Response) to the treatment
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
By interpreting the data you can see a
55-71% of Stage 4 Terminally ill Cancer patients are showing PR (Positive Response) to the treatment
#DDDD
The study has recently been updated to add a series of further Exclusion Criteria's
This will ensure the larger cohort is more fine tuned to prevent these patients which unfortunately are ill to treat to be admitted
Improving the overall efficacy profile of the drug
The study has recently been updated to add a series of further Exclusion Criteria's
This will ensure the larger cohort is more fine tuned to prevent these patients which unfortunately are ill to treat to be admitted
Improving the overall efficacy profile of the drug
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
These findings show very encouraging signs that the treatment fills a large gap in the Oncology market
I anticipate efficacy data to become stronger as the P2 Trial progresses
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
These findings show very encouraging signs that the treatment fills a large gap in the Oncology market
I anticipate efficacy data to become stronger as the P2 Trial progresses
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Due to the initial inflammation and immune response from the drug (Sudo Progression) the results can not be accurately distinguished until the patient has generally undergone 20 weeks on treatment
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Due to the initial inflammation and immune response from the drug (Sudo Progression) the results can not be accurately distinguished until the patient has generally undergone 20 weeks on treatment
#DDDD
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Therefore with this analysis along with factoring in sudo progression.
I believe #DDDD will gain very significant statistical data on treating Terminal Stage 4 Lung and various other cancers in 12 months time
UPDATE
MRx0518/ @Merck KEYTRUDA oncology/cancer trial
Therefore with this analysis along with factoring in sudo progression.
I believe #DDDD will gain very significant statistical data on treating Terminal Stage 4 Lung and various other cancers in 12 months time
#DDDD
MRx0518 x @Merck KEYTRUDAUS Market ONLY (so far)
44,000 Paitents pa
Price of
-MRx0518 $75,000 pa (est)
-KEYTRUDA $168,000 pa
Revenue for MRx0518 (ONLY)
$3.30 billion per annum
Market Expected to grow SIGNIFICANTLY from these levels
https://pharmaintelligence.informa.com/resources/product-content/every-new-cancer-drug-in-2017-cost-100000-or-more
MRx0518 x @Merck KEYTRUDA
US Market ONLY (so far)44,000 Paitents pa
Price of
-MRx0518 $75,000 pa (est)
-KEYTRUDA $168,000 pa
Revenue for MRx0518 (ONLY)
$3.30 billion per annum
Market Expected to grow SIGNIFICANTLY from these levels
https://pharmaintelligence.informa.com/resources/product-content/every-new-cancer-drug-in-2017-cost-100000-or-more
#DDDD
4D commences Phase 2 #COVID19 Therapeutic Trial
MRx-4DP0004
-Excellent safety profile
-Reduces Lung Inflammation by down regulating neutrophils and eosinophils
- While Maintaining anti viral immune response
IMO I think this may drastically improve outcomes
4D commences Phase 2 #COVID19 Therapeutic Trial
MRx-4DP0004
-Excellent safety profile
-Reduces Lung Inflammation by down regulating neutrophils and eosinophils
- While Maintaining anti viral immune response
IMO I think this may drastically improve outcomes
#DDDD
Following the placing today the BoD hold
-19.44% of the company
The placing has also generated substantial US Interest and has hinted at a near term listing on a US exchange
Following the placing today the BoD hold
-19.44% of the company
The placing has also generated substantial US Interest and has hinted at a near term listing on a US exchange
#DDDD
Why I believe @4dpharmaplc are on the cusp of a multi hundred million pound licencing deal for IBD and IBS? https://twitter.com/AimHardy/status/1286223652451647489?s=20
Why I believe @4dpharmaplc are on the cusp of a multi hundred million pound licencing deal for IBD and IBS? https://twitter.com/AimHardy/status/1286223652451647489?s=20
#DDDD
Great Video 'Our Approach' highlighting @4dpharmaplc world leading innovative concept
Harnessing the bodies own Microbiome (Gut Bacteria) to solve genetic imbalances and malfunctions commonly referred to as diseases
https://www.4dpharmaplc.com/en/newsroom/video-and-audio
Great Video 'Our Approach' highlighting @4dpharmaplc world leading innovative concept
Harnessing the bodies own Microbiome (Gut Bacteria) to solve genetic imbalances and malfunctions commonly referred to as diseases
https://www.4dpharmaplc.com/en/newsroom/video-and-audio
#DDDD
Highlighted in this video is the autopsy findings of #COVID19 patients who have died
If is evident Cytokine storm and inflammation, which leads to Pneumonia and ARDS is a significant contributing factor to mortality (death)
Highlighted in this video is the autopsy findings of #COVID19 patients who have died
If is evident Cytokine storm and inflammation, which leads to Pneumonia and ARDS is a significant contributing factor to mortality (death)
#DDDD
@4dpharmaplc
MRx0004- Pre Clinical Indications shows it controls the Immune Response
To have the sufficient capabilities to deal with the issue but prevent over inflammation which can lead to ARDS and Pneumonia
@4dpharmaplc
MRx0004- Pre Clinical Indications shows it controls the Immune Response
To have the sufficient capabilities to deal with the issue but prevent over inflammation which can lead to ARDS and Pneumonia
#DDDD
Further comparative data highlighting the control and reduction of inflammatory cells
Untreated vs MRx0004
Further comparative data highlighting the control and reduction of inflammatory cells
Untreated vs MRx0004
#DDDD
Further Data showing MRx0004 significantly reduces Lung Infiltration and Inflammation
Allowing the lungs to remain porous for gaseous exchange, eradicating the need for ventilation?
Potentially significant treatment to prevent ARDS + Death in Patients with #COVID19
Further Data showing MRx0004 significantly reduces Lung Infiltration and Inflammation
Allowing the lungs to remain porous for gaseous exchange, eradicating the need for ventilation?
Potentially significant treatment to prevent ARDS + Death in Patients with #COVID19
#DDDD
I have now discussed the positive effects of inflammation reduction but what about actually killing the virus?
I have now discussed the positive effects of inflammation reduction but what about actually killing the virus?
#DDDD
COVID19 paitents are seen to have depleted levels of CD4 and CD8
https://www.cell.com/immunity/pdf/S1074-7613(20)30183-7.pdf
COVID19 paitents are seen to have depleted levels of CD4 and CD8
https://www.cell.com/immunity/pdf/S1074-7613(20)30183-7.pdf
#DDDD
“All disease begins in the gut”
Amazing research in the relation between the Microbiome+health
Not everyone will change their diet!
Therefore @4dpharmaplc is exquisitely poised to assist in the therapeutic ailment of modern day illness+disease
“All disease begins in the gut”
Amazing research in the relation between the Microbiome+health
Not everyone will change their diet!
Therefore @4dpharmaplc is exquisitely poised to assist in the therapeutic ailment of modern day illness+disease
#DDDD
Further Data from the Merck KEYTRUDER Collaboration In Oncology (Cancer) Treatment is showing to be very encouraging!
Clinical benefit increasing
25%
33-42%
Why is this early data massively encouraging?
Further Data from the Merck KEYTRUDER
Collaboration In Oncology (Cancer) Treatment is showing to be very encouraging! Clinical benefit increasing
25%
33-42% Why is this early data massively encouraging?
#DDDD
The patients @4dpharmaplc have recruited are patients with no therapeutic options available meaning there is a DESPERATE need for a treatment
Remember my previous tweet when analysing the data this combination is shown to yield even higher clinical benefit %’s
The patients @4dpharmaplc have recruited are patients with no therapeutic options available meaning there is a DESPERATE need for a treatment
Remember my previous tweet when analysing the data this combination is shown to yield even higher clinical benefit %’s
#DDDD
Thread
Here are my thoughts on the clinical validation results of KEYTRUDA with MRx0518 and how this early data is showing revolutionary results for therapeutic treatment
This very well may be the start of a multi billion industry
https://twitter.com/AimHardy/status/1298515350275981318?s=20
Thread
Here are my thoughts on the clinical validation results of KEYTRUDA with MRx0518 and how this early data is showing revolutionary results for therapeutic treatment
This very well may be the start of a multi billion industry
https://twitter.com/AimHardy/status/1298515350275981318?s=20
#DDDD
WOW
Further substantial data released from Italy
signifying the role of Live Bio-therapeutics on Regulation of the Immune Response and improving patients outcomes
BODES WELL AS THIS IS RELATED TO #COVID19
https://www.prnewswire.com/news-releases/first-published-clinical-trial-using-live-biotherapeutic-candidate-in-covid-19-patients-suggests-role-in-improving-outcomes-301092198.html
Credit- @Licensed2trade
WOWFurther substantial data released from Italy
signifying the role of Live Bio-therapeutics on Regulation of the Immune Response and improving patients outcomesBODES WELL AS THIS IS RELATED TO #COVID19
https://www.prnewswire.com/news-releases/first-published-clinical-trial-using-live-biotherapeutic-candidate-in-covid-19-patients-suggests-role-in-improving-outcomes-301092198.html
Credit- @Licensed2trade
#DDDD
I will now go into further favourable data which suggests MRx0004 is perfect for the fight against COVID19
I will now go into further favourable data which suggests MRx0004 is perfect for the fight against COVID19
#DDDD
MRx0004 has shown in studies it boosts and maintains Tregs- control the immune response to self and foreign particles (antigens)
importantly Th1- T cell that promotes cell-mediated immune responses and is required for host defence against intracellular viral pathogens
MRx0004 has shown in studies it boosts and maintains Tregs- control the immune response to self and foreign particles (antigens)
importantly Th1- T cell that promotes cell-mediated immune responses and is required for host defence against intracellular viral pathogens
#DDDD
MRx0004 increased FoxP3+ T A MASTER REGULATOR ensuring the body maintains an optimal balance of immune cells, to prevent lung damage while killing viral pathogens
MRx0004 increased FoxP3+ T A MASTER REGULATOR ensuring the body maintains an optimal balance of immune cells, to prevent lung damage while killing viral pathogens
#DDDD
The aforementioned just disclosed in conjunction with my early analysis of MRx0004 signifies all the relevant biomarkers for the successful treatment of #COVID19
MRx0004 potentially may yield PHENOMENAL results (which are expected towards the end of the year)
The aforementioned just disclosed in conjunction with my early analysis of MRx0004 signifies all the relevant biomarkers for the successful treatment of #COVID19
MRx0004 potentially may yield PHENOMENAL results (which are expected towards the end of the year)
#DDDD
Now taking a look into MRx Platform for CNS diseases such as Parkinson's Disease
Here is a video highlighting
'Parkinson's occurs due to the death DOPAMINE producing neurons'
Now taking a look into MRx Platform for CNS diseases such as Parkinson's Disease
Here is a video highlighting
'Parkinson's occurs due to the death DOPAMINE producing neurons'
#DDDD
Both MRx0005 and MRx0029 have stimulating properties which
-Reduces neurological inflammation
-Protect Dopaminergic Neurons
-Increases Dopamine
Dopamine is the neurological pathway which allows movement
Both MRx0005 and MRx0029 have stimulating properties which
-Reduces neurological inflammation
-Protect Dopaminergic Neurons
-Increases Dopamine
Dopamine is the neurological pathway which allows movement
#DDDD
MRx0004 #COVID Trial
Although it is not a pleasant statistic to report on
Hospital admissions are exponentially rising and will continue to rise into winter
This will accelerate Trial recruitment (90) with potentially a read out by Jan IMO
https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2020/09/COVID-19-daily-admissions-20200923.xlsx
MRx0004 #COVID Trial
Although it is not a pleasant statistic to report on
Hospital admissions are exponentially rising and will continue to rise into winter
This will accelerate Trial recruitment (90) with potentially a read out by Jan IMO
https://www.england.nhs.uk/statistics/wp-content/uploads/sites/2/2020/09/COVID-19-daily-admissions-20200923.xlsx
#DDDD
MRx0005/MRx0029 Targeting Parkinson’s disease
1/2 Causes of Parkinson’s Disease (Body First) originates in the intestines with the Microbiome
https://www.technologynetworks.com/neuroscience/news/second-variant-of-parkinsons-diseases-that-begins-in-the-gut-is-identified-340716
Credit- @coxypete79
MRx0005/MRx0029 Targeting Parkinson’s disease
1/2 Causes of Parkinson’s Disease (Body First) originates in the intestines with the Microbiome
https://www.technologynetworks.com/neuroscience/news/second-variant-of-parkinsons-diseases-that-begins-in-the-gut-is-identified-340716
Credit- @coxypete79
#DDDD
6 Cohorts for their Phase 2 Treatment IN DIFFERENT SOLID TUMOURS
SIMILAR EFFICACY SEEN when compared to @4dpharmaplc Treatment!!
$5.7bn DEAL?!?!?
https://twitter.com/LRamseu/status/1312391912956010498?s=20
6 Cohorts for their Phase 2 Treatment IN DIFFERENT SOLID TUMOURS
SIMILAR EFFICACY SEEN when compared to @4dpharmaplc Treatment!!
$5.7bn DEAL?!?!?
https://twitter.com/LRamseu/status/1312391912956010498?s=20
#DDDD
My thoughts and opinions on Blautix results for IBS https://twitter.com/AimHardy/status/1313802382732603398
My thoughts and opinions on Blautix results for IBS https://twitter.com/AimHardy/status/1313802382732603398
#DDDD
Thread on the potential early revenue generation from US markets alone of MRx0518 which potentially may gain approval as early as next year
$3.52 Billion per annum https://twitter.com/AimHardy/status/1319541051221250048?s=20
Thread on the potential early revenue generation from US markets alone of MRx0518 which potentially may gain approval as early as next year
$3.52 Billion per annum https://twitter.com/AimHardy/status/1319541051221250048?s=20
#DDDD
My thoughts on the earlier than anticipated NASDAQ Listing and how this will propel @4dpharmaplc to a MULTI BILLION 
Valuation
https://twitter.com/AimHardy/status/1319179022899810304?s=20
My thoughts on the earlier than anticipated NASDAQ Listing
and how this will propel @4dpharmaplc to a MULTI BILLION Valuation https://twitter.com/AimHardy/status/1319179022899810304?s=20
#DDDD
@4dpharmaplc CEO Q&A revealing some
very interesting aspects of 4D and why they are the World Leader in a new a evolving therapeutic division... 
Live Bio Therapeutics https://twitter.com/AimHardy/status/1319297760030453760?s=20
@4dpharmaplc CEO Q&A revealing some
very interesting aspects of 4D and why they are the World Leader in a new a evolving therapeutic division... Live Bio Therapeutics https://twitter.com/AimHardy/status/1319297760030453760?s=20
#DDDD
SUPER PHARMA's are still on the lookout for efficacious drugs to treat #COVID19 and are prepared to pay HUNDRED'S OF MILLIONS IN UPFRONT PAYMENTS
Similarly 4D's compound MRx0004 is currently in Phase 2 #COVID19 Trials with results expected Q1 https://twitter.com/AimHardy/status/1319314612110659585?s=20
SUPER PHARMA's are still on the lookout for efficacious drugs to treat #COVID19 and are prepared to pay HUNDRED'S OF MILLIONS IN UPFRONT PAYMENTS
Similarly 4D's compound MRx0004 is currently in Phase 2 #COVID19 Trials with results expected Q1 https://twitter.com/AimHardy/status/1319314612110659585?s=20
#DDDD
COVID Daily Hospital Admissions continue to rise
997 Admissions in a 24 hour Period (21st Oct)
Surely Clinical Enrollment for MRx0004 is expected to be accelerating with 90 Patients to enrol https://twitter.com/AimHardy/status/1308850423902670857
COVID Daily Hospital Admissions continue to rise
997 Admissions in a 24 hour Period (21st Oct)
Surely Clinical Enrollment for MRx0004 is expected to be accelerating with 90 Patients to enrol https://twitter.com/AimHardy/status/1308850423902670857
#DDDD
MRx0004 specifically dampens the immune response...
Dangerously ill coronavirus patients are making
"startling recoveries"
in spite of being at "death's door" after being given
drugs that dial down the immune system
experts have said
http://telegraph.co.uk/news/2020/10/2
MRx0004 specifically dampens the immune response...
Dangerously ill coronavirus patients are making
"startling recoveries" in spite of being at "death's door" after being given
drugs that dial down the immune systemexperts have said
http://telegraph.co.uk/news/2020/10/2
#DDDD
NASDAQ listing expected Mid January
COVID Phase 2 Trial Results I expect shortly after (February)
Can you imagine what US investors will do if MRx0004 follows suit with the aforementioned and is proven to significantly help #COVID Hospitalised Patients https://twitter.com/AimHardy/status/1319883086113476608
NASDAQ listing expected Mid January
COVID Phase 2 Trial Results I expect shortly after (February)
Can you imagine what US investors will do if MRx0004 follows suit with the aforementioned and is proven to significantly help #COVID Hospitalised Patients
https://twitter.com/AimHardy/status/1319883086113476608
#DDDD
Blautix- What has sparked my eye?
The company have stated they are conducting further investigational work regarding their Phase 2 Trial
Specifically Bio Markers for “Sub Groups” and will announce results Q4, refining further/digging deeper than a specific cohort
Blautix- What has sparked my eye?
The company have stated they are conducting further investigational work regarding their Phase 2 Trial
Specifically Bio Markers for “Sub Groups” and will announce results Q4, refining further/digging deeper than a specific cohort
#DDDD
I believe 4D may have stumbled on an entirely different way of looking at/diagnosing the mechanism of disease with this study
Each arm of Blautix in IBS C/D/M ALL generated very similar efficacy 23.4% to 25%
This efficacy across the board is far to similar to ignore
I believe 4D may have stumbled on an entirely different way of looking at/diagnosing the mechanism of disease with this study
Each arm of Blautix in IBS C/D/M ALL generated very similar efficacy 23.4% to 25%
This efficacy across the board is far to similar to ignore
#DDDD
I believe there is a potential to categories specific IBS, primarily by using bio markers
I believe the further investigational work will show strong signals Blautix will cure specific Microbiome deficiencies leading to a Pivotal Phase 3 which will show v high efficacy
I believe there is a potential to categories specific IBS, primarily by using bio markers
I believe the further investigational work will show strong signals Blautix will cure specific Microbiome deficiencies leading to a Pivotal Phase 3 which will show v high efficacy
#DDDD
Overview
10% of the Global Population is expected to have IBS
Blautix has shown to be 25% effective across the board for improving peoples outcomes for IBS
That indicates the potential market for Blautix is effectively 2.5% of the global population
Overview
10% of the Global Population is expected to have IBS
Blautix has shown to be 25% effective across the board for improving peoples outcomes for IBS
That indicates the potential market for Blautix is effectively 2.5% of the global population
#DDDD
Blautix is safe with No SAE
This leads me to believe even with 25% efficacy
This could become the first line of Therapy routinely prescribed by GP’s
around the globe (potentially OTC Treatment)
With an initial 6-8 week prescription to see if benefits are seen
Blautix is safe with No SAE
This leads me to believe even with 25% efficacy
This could become the first line of Therapy routinely prescribed by GP’saround the globe (potentially OTC Treatment)With an initial 6-8 week prescription to see if benefits are seen
#DDDD
11th Nov I hope you are ready
Why would you host a presentation with an associate professor from
THE BEST CANCER HOSPITAL IN THE WORLD
discussing your drug in
Pancreatic (Gastrointestinal) Cancer
UNLESS YOU HAD SOME NEW GROUND BREAKING NEWS TO PUBLISH...
11th Nov I hope you are ready
Why would you host a presentation with an associate professor from
THE BEST CANCER HOSPITAL IN THE WORLD discussing your drug in
Pancreatic (Gastrointestinal) Cancer
UNLESS YOU HAD SOME NEW GROUND BREAKING NEWS TO PUBLISH...
#DDDD
MRx0518 is already showing great signs of Efficacy in Lung and Kidney Cancer...
Are we now going to receive news on a further application to treat Pancreatic Cancer?
MRx0518 is already showing great signs of Efficacy in Lung and Kidney Cancer...
Are we now going to receive news on a further application to treat Pancreatic Cancer?
#DDDD
Thread
Update of MRx0518 at SITC and the subtle and early indications presented for the long term growth and validation of the MRx Platform https://twitter.com/AimHardy/status/1326539660638605313?s=20
Thread
Update of MRx0518 at SITC and the subtle and early indications presented for the long term growth and validation of the MRx Platform
https://twitter.com/AimHardy/status/1326539660638605313?s=20
#DDDD $LBPS
Thread
How MRx0518 has the potential to penetrate multiple indications of Cancer due to its efficacy and excellent safety profile https://twitter.com/AimHardy/status/1327381385267585026
Thread
How MRx0518 has the potential to penetrate multiple indications of Cancer due to its efficacy and excellent safety profile
https://twitter.com/AimHardy/status/1327381385267585026
#DDDD
@GSK
'WE think that modulation of the Lung Microbiome + the immune response to the Lung Microbiome will help us to modify diseases in a way that ISN'T CURRENTLY POSSIBLE with existing therapies...
leading us more toward CURE of the disease' https://www.gsk.com/en-gb/behind-the-science/innovation/the-lung-microbiome-and-the-future-management-of-respiratory-disease/
@GSK
'WE think that modulation of the Lung Microbiome + the immune response to the Lung Microbiome will help us to modify diseases in a way that ISN'T CURRENTLY POSSIBLE with existing therapies...
leading us more toward CURE of the disease' https://www.gsk.com/en-gb/behind-the-science/innovation/the-lung-microbiome-and-the-future-management-of-respiratory-disease/
#DDDD
BLAUTIX
COMPARABLE
to
FDA APPROVED
IBS Drugs
Could Blautix become the the initial first line of treatment offered
Globally for IBS across all indications?
BLAUTIX
COMPARABLE to
FDA APPROVED IBS Drugs
Could Blautix become the the initial first line of treatment offered
Globally for IBS across all indications?
#DDDD
BLAUTIX
Now directors have laid it out very clearly
YOU CAN SEE WHY Blautix IS GAINING SUBSTANTIAL INTEREST FROM MAJOR INTERNATIONAL COMPANIES IN THE SPACE
You only need to look at the deals which are being signed in the area
(BUT NOT IN THIS INDICATION)
BLAUTIX
Now directors have laid it out very clearly
YOU CAN SEE WHY Blautix IS GAINING SUBSTANTIAL INTEREST FROM MAJOR INTERNATIONAL COMPANIES IN THE SPACE
You only need to look at the deals which are being signed in the area
(BUT NOT IN THIS INDICATION)
#DDDD
A recent accelerated approval for an ADC produced by @GSK for Multiple Myeloma had an Overall Response Rate of 31% and has significant side effects
Currently MRx0518 has shown a similar ORR of 25% with an excellent safety profile
https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/
A recent accelerated approval for an ADC produced by @GSK for Multiple Myeloma had an Overall Response Rate of 31% and has significant side effects
Currently MRx0518 has shown a similar ORR of 25% with an excellent safety profile
https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/
#DDDD
Tocilizumab the “anti inflammatory drug” to receive approval for treatment of COVID19
https://www.bbc.co.uk/news/health-55002339
“an encouraging result which SUGGESTS that OTHER MORE TARGETED ANTI-INFLAMMATORY DRUGS may help”
MRx0004 a LBP that SPECIFICALLY targets Lung Inflammation
Tocilizumab the “anti inflammatory drug” to receive approval for treatment of COVID19
https://www.bbc.co.uk/news/health-55002339
“an encouraging result which SUGGESTS that OTHER MORE TARGETED ANTI-INFLAMMATORY DRUGS may help”
MRx0004 a LBP that SPECIFICALLY targets Lung Inflammation
#DDDD
4D are now 5 months into their P2 trial for MRx0518 x KEYTRUDA and have recently requested an FDA meeting for accelerated approval which is now planned for Q1 2021...
4D are now 5 months into their P2 trial for MRx0518 x KEYTRUDA and have recently requested an FDA meeting for accelerated approval which is now planned for Q1 2021...
#DDDD
With so little patient enrolment to date (Likely less than 100) why are 4D going for approval so early into trials?
Is the growing body of evidence showing large statistical significance/benefit for these desperately in need Stage 4 Cancer Patients?
With so little patient enrolment to date (Likely less than 100) why are 4D going for approval so early into trials?
Is the growing body of evidence showing large statistical significance/benefit for these desperately in need Stage 4 Cancer Patients?
#DDDD
4D have shown some remarkable results already with 70%+ tumour shrinkage in a patient with Stage 4 cancer
You have to remember these patients are terminally ill after having exhausted multiple different treatments which all have failed
4D have shown some remarkable results already with 70%+ tumour shrinkage in a patient with Stage 4 cancer
You have to remember these patients are terminally ill after having exhausted multiple different treatments which all have failed
#DDDD
Another encouraging update
MRx0518 shows most promise in Lung Cancer (NSCLC) and more efficacy as a monotherapy ALONE than an already approved drug which is actually approved for FIRST LINE OF THERAPY
Another encouraging update
MRx0518 shows most promise in Lung Cancer (NSCLC) and more efficacy as a monotherapy ALONE than an already approved drug which is actually approved for FIRST LINE OF THERAPY
#DDDD
Developing on why MRx0518 may be ground breaking for Lung Cancer
Observe this patient NSCLC
They had a STAGGERING 7 lines of therapy with no meaningful benefit before 4D's trial
Now they have seen a continued steady shrinkage of the Tumour
Data- 8 months ago
Developing on why MRx0518 may be ground breaking for Lung Cancer
Observe this patient NSCLC
They had a STAGGERING 7 lines of therapy with no meaningful benefit before 4D's trial
Now they have seen a continued steady shrinkage of the Tumour
Data- 8 months ago
#DDDD $LBPS
This Stage 4 Terminally ill patient that had exhausted ALL other treatments STILL remains on treatment 18 MONTHS LATER using MRx0518
STILL continuing Progression Free Survival and Tumour Shrinkage
This is HUGE
Now lets look at ORR...
This Stage 4 Terminally ill patient that had exhausted ALL other treatments STILL remains on treatment 18 MONTHS LATER using MRx0518
STILL continuing Progression Free Survival and Tumour Shrinkage
This is HUGE
Now lets look at ORR...
#DDDD $LBPS
Objective Response Rate is currently at 33%
However taking into account the ground breaking results just discussed, the current data is skewed due to patient withdrawal due to factors unrelated to MRx0518
ORR is likely to improve much further in NSCLC from here
Objective Response Rate is currently at 33%
However taking into account the ground breaking results just discussed, the current data is skewed due to patient withdrawal due to factors unrelated to MRx0518
ORR is likely to improve much further in NSCLC from here
#DDDD
As shown on the graph the 2 other NSCLC participants withdrew before the first assessment at 9 weeks (This is the point you will BEGIN to see meaningful benefit)
The patients also did not discontinue due to drug related side effects
As shown on the graph the 2 other NSCLC participants withdrew before the first assessment at 9 weeks (This is the point you will BEGIN to see meaningful benefit)
The patients also did not discontinue due to drug related side effects
#DDDD $LBPS
Therefore to date the ONLY patient within the NSCLC cohort which continued treatment up to the first meaningful assessment point shows VERY SIGNIFICANT clinical benefit
Adjusted ORR for NSCLC (Lung Cancer) is a HUGE
100%
Continuing to show PFS 18 Months+
Therefore to date the ONLY patient within the NSCLC cohort which continued treatment up to the first meaningful assessment point shows VERY SIGNIFICANT clinical benefit
Adjusted ORR for NSCLC (Lung Cancer) is a HUGE
100%Continuing to show PFS 18 Months+
#DDDD $LBPS
Thread
Identifying similarities found between MRx0518 and Iova's TIL Therapy
A NASDAQ listed company developing similar very safe and efficacious drug pathways
The only difference $IOVA valued 3700%(YES 37 TIMES) higher than 4D Currently https://twitter.com/AimHardy/status/1333888698602168322?s=20
Thread
Identifying similarities found between MRx0518 and Iova's TIL Therapy
A NASDAQ listed company developing similar very safe and efficacious drug pathways
The only difference $IOVA valued 3700%
(YES 37 TIMES) higher than 4D Currently https://twitter.com/AimHardy/status/1333888698602168322?s=20
#DDDD
Commentary on $GLSI and likelihood of multiple near term value inflection point for 4D Pharma Q1 2021 https://twitter.com/AimHardy/status/1336766100391026689?s=20
Commentary on $GLSI and likelihood of multiple near term value inflection point for 4D Pharma Q1 2021 https://twitter.com/AimHardy/status/1336766100391026689?s=20
#DDDD
Incredible safety profile
NO Moderate Side Effects atall (All mild)
All while yielding clinical benefit in terminally ill patients which have exhausted all other treatment methods
A effective treatment that shows the possibility to be stacked with many other combos
Incredible safety profile
NO Moderate Side Effects atall (All mild)
All while yielding clinical benefit in terminally ill patients which have exhausted all other treatment methods
A effective treatment that shows the possibility to be stacked with many other combos
#DDDD $LBPS
Information on how the Microbiome can enhance immune activation increasing efficacy of drugs.. in particular VACCINES
4D Pharma has a joint development agreement with @Merck valued @ $1bn+ specifically targeting vaccine innovation
Information on how the Microbiome can enhance immune activation increasing efficacy of drugs.. in particular VACCINES
4D Pharma has a joint development agreement with @Merck valued @ $1bn+ specifically targeting vaccine innovation
#DDDD $LBPS
This one specific study highlighting the potential of
Live Bio Therapeutics (Microbiome)
To reactivate the immune system in
-Elderly
-Antibiotic Resistant Patients
Improving efficacy of vaccinations to sufficiently generate Anti Bodies
This one specific study highlighting the potential of
Live Bio Therapeutics (Microbiome)
To reactivate the immune system in
-Elderly
-Antibiotic Resistant Patients
Improving efficacy of vaccinations to sufficiently generate Anti Bodies
